Novel Oral Anticoagulant Reversal Agent Tops AJPB Week in Review

5. FDA OKs Treatment Combo for Advanced Renal Cell Carcinoma

Nivolumab plus low-dose ipilimumab combination is the first and only treatment to show significantly superior survival compared with sunitinib in intermediate- and poor-risk advanced renal cell carcinoma. Read more.

4. Congress, Medical Societies Address Approaches to Combat Opioid Crisis

Two different approaches to attack the opioid-fueled substance use disorder (SUD) crisis are on display this week. Read more.

3. Artificial Pancreas Improves Blood Sugar Control in Type 1 Diabetes

An artificial pancreas can improve blood sugar control for people with type 1 diabetes (T1D), according to a new study. Read more.

2. Childhood Factors May Contribute to COPD Risk

Childhood factors predisposed children to lung function decline and chronic obstructive pulmonary disease (COPD) as adults, according to 2 recent studies. Read more.

1. FDA Approves First Novel Oral Anticoagulant Reversal Agent

The approval is the first of its kind for a reversal agent of a novel oral anticoagulant (NOAC). Read more.